Uncategorized

Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology

by Business Wire • 2023/04/12 • 0 Comments

HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NOVALIQ ANNOUNCES PUBLICATION OF SECOND PIVOTAL PHASE 3 TRIAL DATA ON CYCLASOL 0.1% (CYCLOSPORINE OPHTHALMIC SOLUTION) IN JAMA OPHTHALMOLOGY

← Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3

Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing →

Post navigation